Aumolertinib study for European patients with lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted therapy, Aumolertinib, for adults with a specific type of advanced lung cancer (non-small cell lung cancer) that has certain genetic changes (EGFR mutations). The goal is to see if the drug can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and of European descent living in a European country.
- You must have a type of lung cancer called non-small cell lung cancer that is advanced (stage IIIB/IV) or has come back after treatment, and has an EGFR mutation (ex19del, L858R, or T790M).
- You must have good organ function (kidney, liver, bone marrow) and be well enough to be up and about (ECOG score 0 or 1).
- You must not have had certain previous treatments, like a third-generation EGFR-TKI (e.g., osimertinib), or need to wait a specific time since other treatments.
- You cannot have untreated or unstable brain metastases, uncontrolled infections, heart problems, or a history of lung scarring (interstitial lung disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two targeted pills, aumolertinib and osimertinib, as the first treatment for people with advanced EGFR-mutant lung cancer. It aims to see which one works better with fewer side effects.
This trial tests whether adding a new targeted drug (SHR-A2009) to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. It's for those who haven't had treatment yet.
This study tests how a lung cancer pill called aumolertinib affects the levels of another drug (midazolam) in your body. It is for people with advanced NSCLC whose tumors have specific EGFR gene changes.
This trial tests combining a targeted pill (almonertinib) with precise radiation to the lung for people with advanced non-small cell lung cancer that has an EGFR mutation. The goal is to see if this combination works better than the pill alone.
This trial tests a new targeted therapy called Firmonertinib for people with advanced EGFR-mutated non-small cell lung cancer. It uses a special blood test (liquid biopsy) to guide treatment and adjust it over time, aiming to make the therapy more personalized.
This Phase 3 trial tests whether almonertinib given after standard chemoradiation can help people with stage III, non-surgical lung cancer live longer and/or control the cancer. It is for tumors with specific EGFR mutations linked to sensitivity to EGFR-targeted medicines.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.